CYCC - サイクラセル・ファ―マシュ―ティカルズ （Cyclacel Pharmaceuticals Inc.）

Shares of biopharmaceutical company Cyclacel Pharmaceuticals (CYCC) have added 13.2% in premarket trading on Tuesday after announcing publication of preclinical data confirming that…

-New Preclinical Data Highlight Fadraciclib’s Apoptosis Enabling Mechanism in Leukemia-

Cyclacel Pharmaceuticals press release (CYCC): Q4 GAAP EPS of -$1.34.As of December 31, 2021, cash and cash equivalents totaled $36.6 million, compared to $33.4 million as of December…

-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 –

Geode Capital Management LLC increased its holdings in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) by 143.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,860 shares of the biotechnology companys stock after buying an additional 29,956 shares during the []

Wall Street brokerages expect that Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) will report earnings per share of ($0.66) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Cyclacel Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.71) and the highest estimate coming in at ($0.63). Cyclacel Pharmaceuticals posted earnings per []

Cyclacel Pharmaceuticals (NASDAQ:CYCC) had its price objective dropped by research analysts at LADENBURG THALM/SH SH from $18.00 to $17.00 in a research note issued to investors on Thursday, The Fly reports. The firm presently has a buy rating on the biotechnology companys stock. LADENBURG THALM/SH SHs price objective would suggest a potential upside of 264.03% []

Boothbay Fund Management LLC decreased its holdings in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) by 66.7% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,545 shares of the biotechnology companys stock after selling 21,089 shares during the period. Boothbay Fund Management LLC owned approximately 0.11% of Cyclacel []

BERKELEY HEIGHTS, N.J. , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in three

News Ghana, Latest Updates and Breaking News of Ghana, GNA, https://newsghana.com.gh/community-youth-cultural-centre-runs-entrepreneurship-training-camp-for-the-youth/The Community Youth Cultural Centre (CYCC) has organized a week-long programme in Accra to build the vocational and entrepreneurship capacity of some youth. The skills training programme held under the auspices of the Ministry of Tourism, Arts and Culture and the National Commission of Culture, []

- Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib - - Additional Phase 1/2 Trials for Fadraciclib and CYC140 Expected to Follow - - Cash Runway to Early 2023 - - Conference Call Scheduled August 11, 2021 at 4:30 p.m. ET -